NCT03703856CompletedPhase 4
Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 16 Apr 2026
Brief summary (registry, in English)
The effects of the medication, memantine, on brain functions and the symptoms of Alzheimer's Disease will be tested
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 53 (actual)
- First submitted
- 9 Oct 2018
- Start date
- 31 Jan 2019
- Primary completion date
- 8 Jan 2025
- Lead sponsor
- University of California, San Diego
- Diseases
- Alzheimer disease
- NCT number
- NCT03703856
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 53
- From 31 Jan 2019 to the primary completion date, 8 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Inclusion:
- Alzheimer's Disease Research Center-confirmed diagnosis of AD
- Mini-Mental State Examination (MMSE) score 10-22 OR a Montreal Cognitive Assessment (MOCA) score of 15-24
- Age 50-83 y
- Knowledgeable caregiver
- Ambulatory
- Medically stable;
- Audiometric testing (detection \< or = to 45 db(A) at 1000 Hz)
- Informed consent
- Exclusion:
- Active systemic illness (e.g. heart disease, liver failure, renal insufficiency, cancer, HIV, tuberculosis, Hepatitis C)
- Current psychiatric or neurologic illness other than AD
- History of vascular disease, myocardial infarction, cerebrovascular accidents, transient ischemic attack, seizure, head injury with loss of consciousness; substance dependence (including alcohol and Opioid)
- Past treatment with memantine; unable to tolerate acetylcholinesterase inhibitor
- Investigational drug treatment \< 30 d of screening
- Current meds: amantadine, riluzole, other pro-cognitive medication, opioids
- Positive urine toxicology for non-prescribed psychoactive substance
- Actively enrolled in cognitive remediation therapy
Age in the registry: 50 years to 83 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical Teaching Facility (CTF-B102) at UCSD Medical Center Coordinator of this site? Confirm its status | San Diego | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.